On the other hand, to date, three GLP-1 RAs have demonstrated a reduction in the MACE in patients with T2DM (liraglutide, subcutaneous semaglutide, dulaglutide) (60) (Table 1). Here, GLP1R is linked to type 2 diabetes mellitus.